Free Trial
NASDAQ:HSCS

Heart Test Laboratories (HSCS) Stock Price, News & Analysis

Heart Test Laboratories logo
$2.96 +0.05 (+1.72%)
Closing price 03:58 PM Eastern
Extended Trading
$3.00 +0.04 (+1.35%)
As of 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Heart Test Laboratories Stock (NASDAQ:HSCS)

Key Stats

Today's Range
$2.91
$3.15
50-Day Range
$2.86
$3.99
52-Week Range
$2.36
$13.50
Volume
10,669 shs
Average Volume
127,930 shs
Market Capitalization
$3.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00
Consensus Rating
Buy

Company Overview

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Remove Ads

Heart Test Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

HSCS MarketRank™: 

Heart Test Laboratories scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Heart Test Laboratories has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Heart Test Laboratories has only been the subject of 1 research reports in the past 90 days.

  • Read more about Heart Test Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for Heart Test Laboratories are expected to grow in the coming year, from ($10.01) to ($8.80) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Heart Test Laboratories is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Heart Test Laboratories is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Heart Test Laboratories has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.52% of the float of Heart Test Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Heart Test Laboratories has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Heart Test Laboratories has recently decreased by 12.03%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Heart Test Laboratories does not currently pay a dividend.

  • Dividend Growth

    Heart Test Laboratories does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.52% of the float of Heart Test Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Heart Test Laboratories has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Heart Test Laboratories has recently decreased by 12.03%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Heart Test Laboratories has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Heart Test Laboratories this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    2 people have added Heart Test Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Heart Test Laboratories insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.80% of the stock of Heart Test Laboratories is held by insiders.

  • Percentage Held by Institutions

    Only 17.24% of the stock of Heart Test Laboratories is held by institutions.

  • Read more about Heart Test Laboratories' insider trading history.
Receive HSCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heart Test Laboratories and its competitors with MarketBeat's FREE daily newsletter.

HSCS Stock News Headlines

Ascendiant Capital Markets Weighs in on HSCS Q4 Earnings
Trump Makes Major Crypto Announcement
Trump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.
See More Headlines

HSCS Stock Analysis - Frequently Asked Questions

Heart Test Laboratories' stock was trading at $3.82 at the start of the year. Since then, HSCS shares have decreased by 22.5% and is now trading at $2.96.
View the best growth stocks for 2025 here
.

Heart Test Laboratories, Inc. (NASDAQ:HSCS) issued its earnings results on Thursday, March, 13th. The company reported ($2.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.53) by $0.04.

Heart Test Laboratories shares reverse split on Friday, May 17th 2024. The 1-100 reverse split was announced on Friday, May 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Heart Test Laboratories (HSCS) raised $9 million in an initial public offering on Wednesday, June 15th 2022. The company issued 1,800,000 shares at a price of $4.50-$5.50 per share. The Benchmark Company served as the underwriter for the IPO.

Shares of HSCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Heart Test Laboratories investors own include Meta Platforms (META), Cardio Diagnostics (CDIO), Invesco QQQ (QQQ), RH (RH), Exxon Mobil (XOM), Amarin (AMRN) and American Express (AXP).

Company Calendar

Last Earnings
3/13/2025
Today
3/24/2025
Fiscal Year End
4/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:HSCS
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.00
High Stock Price Target
$14.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+326.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,610,000.00
Pretax Margin
-50,833.34%

Debt

Sales & Book Value

Annual Sales
$14,700.00
Price / Cash Flow
N/A
Book Value
$11.16 per share
Price / Book
0.27

Miscellaneous

Free Float
962,000
Market Cap
$3.30 million
Optionable
Not Optionable
Beta
2.77
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:HSCS) was last updated on 3/24/2025 by MarketBeat.com Staff
From Our Partners